C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway

Maria Eugenia Sabbatini, Myrian R. Rodríguez, Natalia S. Corbo, Marcelo S. Vatta, Liliana G. Bianciotti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalEuropean Journal of Pharmacology
Volume524
Issue number1-3
DOIs
StatePublished - Nov 7 2005

Fingerprint

C-Type Natriuretic Peptide
Brain
Guanylate Cyclase-Coupled Receptors
Hexamethonium
Natriuretic Peptides
Adrenergic Antagonists
Secretin
Vagotomy
Brain Natriuretic Peptide
Vasoactive Intestinal Peptide
Cholecystokinin
NG-Nitroarginine Methyl Ester
Atrial Natriuretic Factor
Atropine
Amides
Nitric Oxide Synthase
Neurotransmitter Agents
Central Nervous System

Keywords

  • C-type natriuretic peptide
  • Central nervous system
  • Exocrine pancreatic secretion
  • Natriuretic peptide receptor A
  • Natriuretic peptide receptor B
  • c-ANP-(4-23) amide
  • cGMP pathway

ASJC Scopus subject areas

  • Pharmacology

Cite this

C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway. / Sabbatini, Maria Eugenia; Rodríguez, Myrian R.; Corbo, Natalia S.; Vatta, Marcelo S.; Bianciotti, Liliana G.

In: European Journal of Pharmacology, Vol. 524, No. 1-3, 07.11.2005, p. 67-74.

Research output: Contribution to journalArticle

Sabbatini, Maria Eugenia ; Rodríguez, Myrian R. ; Corbo, Natalia S. ; Vatta, Marcelo S. ; Bianciotti, Liliana G. / C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway. In: European Journal of Pharmacology. 2005 ; Vol. 524, No. 1-3. pp. 67-74.
@article{a7fdaca324624919ab1a9dfd807a0262,
title = "C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway",
abstract = "C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.",
keywords = "C-type natriuretic peptide, Central nervous system, Exocrine pancreatic secretion, Natriuretic peptide receptor A, Natriuretic peptide receptor B, c-ANP-(4-23) amide, cGMP pathway",
author = "Sabbatini, {Maria Eugenia} and Rodr{\'i}guez, {Myrian R.} and Corbo, {Natalia S.} and Vatta, {Marcelo S.} and Bianciotti, {Liliana G.}",
year = "2005",
month = "11",
day = "7",
doi = "10.1016/j.ejphar.2005.09.015",
language = "English (US)",
volume = "524",
pages = "67--74",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway

AU - Sabbatini, Maria Eugenia

AU - Rodríguez, Myrian R.

AU - Corbo, Natalia S.

AU - Vatta, Marcelo S.

AU - Bianciotti, Liliana G.

PY - 2005/11/7

Y1 - 2005/11/7

N2 - C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.

AB - C-type natriuretic peptide (CNP) is the major natriuretic peptide in the brain and its mRNA has been reported in the central nervous system, which supports local synthesis and its role as a neuromodulator. The aim of the present work was to study the effect of centrally applied CNP on pancreatic secretion. Rats were fitted with a lateral cerebroventricular cannula one-week before secretion studies. The central administration of CNP dose-dependently enhanced pancreatic fluid and protein output. CNP response was diminished by atropine and hexamethonium, but it was abolished by vagotomy. Neither adrenergic antagonists nor the administration of (d-p-Cl-Phe6,Leu 17)-vasoactive intestinal peptide (VIP antagonist) or N ω Nitro-l arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor) affected CNP response. The effect induced by CNP was mimicked by 8-Br-cGMP but not by c-ANP-(4-23) amide (selective agonist of the natriuretic peptide receptor C). Furthermore, CNP interacted with cholecystokinin (CCK) and secretin in the brain to modify pancreatic secretion. Present findings show that centrally applied CNP enhanced pancreatic secretion through a vagal pathway and suggest that CNP response is mediated by the activation of natriuretic peptide guanylyl cyclase coupled receptors in the brain.

KW - C-type natriuretic peptide

KW - Central nervous system

KW - Exocrine pancreatic secretion

KW - Natriuretic peptide receptor A

KW - Natriuretic peptide receptor B

KW - c-ANP-(4-23) amide

KW - cGMP pathway

UR - http://www.scopus.com/inward/record.url?scp=27744594085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744594085&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.09.015

DO - 10.1016/j.ejphar.2005.09.015

M3 - Article

C2 - 16263110

AN - SCOPUS:27744594085

VL - 524

SP - 67

EP - 74

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -